Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Lab Sensor Solutions will partner with MarketLab to distribute T-Tracks, which tracks, in real time, the temperature and location of clinical samples in transit, preventing laboratory specimen spoilage and loss and ensuring regulatory compliance. T-Tracks data are delivered to lab personnel’s desktops, laptops, and mobile devices.
The results of a large, multicenter prospective clinical study that validates the ability of MeMed’s ImmunoXpert in vitro diagnostic blood test to determine whether a patient has an acute bacterial or viral infection was published in the March 18, 2015 online edition of Plos One.
Terumo BCT has received 510(k) clearance for a labeling change, extending the storage of platelets in plasma from five days to seven days, as well as offering wireless capability for the software applications used with Terumo BCT’s Trima Accel Automated Blood Collection System. This clearance adds to the flexibility and productivity of the Trima Accel system, a device that offers single-needle procedures for a more comfortable donation experience.
Qiagen and Biotype Diagnostics have entered into a partnership to establish Biotype Innovation GmbH. The new company will develop and commercialize molecular diagnostic workflows initially for personalized health care applications based on Qiagen’s proprietary ModaPlex platform, which enables customers to detect, characterize, and measure up to 100 parameters simultaneously.
The Insulin and Proinsulin ELISA kits from Enzo Life Sciences allow for the quantitative determination of insulin and proinsulin in serum and plasma. The kits provide a highly sensitive measurement, detecting as little as 0.622 µIU/mL (insulin) and 0.17 pM (proinsulin), deliver fully quantitative results that surpass semiquantitative Western blot analysis, and can analyze up to 40 samples in duplicate in three hours.
CLSI released new and revised standards on point-of-care testing in relation to glucose measuring and monitoring. “Effects of Different Sample Types on Glucose Measurements, 1st Edition (POCT06-Ed1)” provides information to assist the clinical and point-of-care staff in result and measurement procedure comparisons of glucose tests and is intended for use by clinicians, point-of-care teams, pathologists, laboratory directors, and manufacturers of glucose testing devices.
Illumina launched Illumina SeqLab, an integrated solution for customers with HiSeq X Systems designed to increase laboratory efficiency for population-scale, human whole-genome sequencing.
New England Biolabs has released WarmStart RTx Reverse Transcriptase, a novel, thermostable reverse transcriptase, specifically designed for nucleic acid detection.
Bio-Rad Laboratories released human-serum–based Lyphochek Allergen sIgE quality controls to monitor the precision of in vitro allergy test procedures.
UTAK Laboratories released its SMx (specialty matrix) Product Line. SMx bulk matrices and quality control products are now offered as SMx Oral Fluid, SMx Sweat, SMx Hair, SMx Urine, SMx Serum, SMx Cerebral Spinal Fluid, and SMx Synovial Fluid.
